Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.2197 | 0.5 | 0.5 |
Echinococcus granulosus | acetylcholinesterase | 0.2197 | 0.5 | 0.5 |
Echinococcus granulosus | acetylcholinesterase | 0.2197 | 0.5 | 0.5 |
Echinococcus granulosus | carboxylesterase 5A | 0.2197 | 0.5 | 0.5 |
Loa Loa (eye worm) | acetylcholinesterase 1 | 0.2197 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.2197 | 0.5 | 0.5 |
Brugia malayi | Carboxylesterase family protein | 0.2197 | 0.5 | 0.5 |
Echinococcus multilocularis | acetylcholinesterase | 0.2197 | 0.5 | 0.5 |
Loa Loa (eye worm) | carboxylesterase | 0.2197 | 0.5 | 0.5 |
Echinococcus multilocularis | acetylcholinesterase | 0.2197 | 0.5 | 0.5 |
Echinococcus multilocularis | carboxylesterase 5A | 0.2197 | 0.5 | 0.5 |
Schistosoma mansoni | family S9 non-peptidase homologue (S09 family) | 0.2197 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
ED50 (functional) | mg kg-1 | Ability to antagonise intraperitoneal dose; inactive (<10% antagonism) at 30 mg/kg is represented as I-30. | ChEMBL. | 3039136 |
ED50 (functional) | mg kg-1 | Ability to antagonise intraperitoneal dose; inactive (<10% antagonism) at 30 mgjkg is represented as I-30. | ChEMBL. | 3039136 |
Inhibition (functional) | = 19 % | Ability to inhibit the uptake of [3H]-dopamine (DA) 0.1 uM concentration at rat brain synaptosomes | ChEMBL. | 3039136 |
Inhibition (functional) | = 32 % | Ability to inhibit the uptake of [3H]- serotonin(5-HT) 0.1 microM concentration at rat brain synaptosomes | ChEMBL. | 3039136 |
Inhibition (functional) | = 69 % | Ability to inhibit the uptake of [3H]-norepinephrine (NE) 0.1 microM concentration at rat brain synaptosomes | ChEMBL. | 3039136 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.